Get the Stockscreener App
3.41
1.79%
0.06
After Hours:
3.45
0.04
+1.17%
Aptose Biosciences Inc stock is traded at $3.41, with a volume of 18,714.
It is up +1.79% in the last 24 hours and down -36.89% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$3.35
Open:
$3.44
24h Volume:
18,714
Relative Volume:
0.05
Market Cap:
$7.31M
Revenue:
-
Net Income/Loss:
$-35.80M
P/E Ratio:
-1.1481
EPS:
-2.97
Net Cash Flow:
$-37.18M
1W Performance:
+31.66%
1M Performance:
-36.89%
6M Performance:
-69.20%
1Y Performance:
-92.81%
1-Day Range:
$3.11
$3.5265
1-Week Range:
$2.57
$3.5265
52-Week Range:
$2.56
$51.61
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
3.41 | 7.31M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences (NASDAQ:APTO) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences (TSE:APS) Upgraded at Alliance Global Partners - Defense World
Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update - MarketBeat
Investor Network: Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences Inc. to Host Earnings Call - ACCESS Newswire
Aptose Biosciences initiated with a Speculative Buy at Alliance Global Partners - TipRanks
Aptose's leukemia drug cleared to double clinical trial dose - MSN
Aptose Biosciences Inc (NASDAQ: APTO) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences finalizes reverse stock split - Investing.com India
Aptose Biosciences Stock to Reverse Split on Wednesday, February 26th (NASDAQ:APTO) - Defense World
Aptose Biosciences finalizes reverse stock split By Investing.com - Investing.com Canada
Aptose Announces Positive Clinical Safety Review Committee - GlobeNewswire
Aptose advances AML treatment with higher dose in trial By Investing.com - Investing.com Nigeria
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
Aptose Biosciences Moves Forward With TUS Escalation In TUSCANY Trial After Positive Data - Nasdaq
Aptose's leukemia drug cleared to double clinical trial dose | 2025-02-20 | Investing News - Stockhouse Publishing
Aptose advances AML treatment with higher dose in trial - Investing.com India
Aptose Biosciences Brief: This Amid "Complete Responses and Favorable Safety in First Cohort" - Marketscreener.com
Aptose Biosciences Brief: Announcing "Positive" Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib - Marketscreener.com
Breakthrough in AML Treatment? Aptose's Triple Drug Therapy Achieves Complete Responses in First Trial Cohort - StockTitan
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga India
US Stocks Likely To Open Lower Following Fresh Records From Previous Session: Expert Says, 'Don't Be Scared Of New Highs' - Benzinga
Aptose Biosciences plans reverse stock split to meet Nasdaq rules By Investing.com - Investing.com Canada
Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance - MSN
Aptose Biosciences Announces Reverse Share Split - TipRanks
Aptose Biosciences plans reverse stock split to meet Nasdaq rules - Investing.com India
Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements - Nasdaq
Aptose Announces Reverse Share Split - GlobeNewswire
Aptose Takes Bold Action: 30-to-1 Share Consolidation to Secure Nasdaq Future - StockTitan
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet - Benzinga India
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga India
Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners - MSN
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Biosciences Inc. (NASDAQ: APTO) Issues Press Release on February 12, 2025 - Defense World
Aptose Biosciences Secures $25M Share Purchase Agreement - TipRanks
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewswire
Aptose Biosciences secures $25 million equity facility By Investing.com - Investing.com Canada
Aptose Biosciences Enters $25 Million Common Share Purchase Agreement to Support AML Therapy Development - Nasdaq
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):